Alexium and Colinton streamlining efficiencies and optimising growth
Shares in Alexium International Group Limited (ASX: AJX) have increased 50% since June, buoyed by promising operational news flow in the preceding months, culminating in a strengthening of the company’s board and the entry of an institutional investor in Colinton Capital Partners, headed up by Simon Moore one of Australia’s leading entrepreneurs.
Moore was managing director and global partner of The Carlyle Group between 2005 and 2016 where he was involved with shaping the strategy of many corporations, leading significant turnarounds, and managing numerous corporate transactions across small and large companies.
Finfeed's Damian Hajda had the opportunity to catch up with Moore last week, and he provided some valuable insights into what it takes to succeed as an investor that partners with business owners and senior management with a view to unlocking the growth potential of emerging businesses.
In a nutshell, Colinton is a constructive investor, leveraging its collective experience and that of its broader networks in order to add value to the businesses it partners with.
As a general rule, Colinton invests in growing businesses with strong market positions, positive earnings and enterprise values from $20 million to $200 million.
The group specialises in providing flexible capital solutions for expansion, succession planning, management buy-outs/buy-ins, public-to-private transactions and active minority public positions, an ideal partner for Alexium in terms of negotiating the corporate world.
All creatures great and small
During Moore’s time at Carlyle, the group was an early stage investor in what is now a major logistics enterprise in QUBE Holdings (ASX: QUB), taking it from a market capitalisation of about $300 million to $500 million.
He was also involved with the privatisation of Coates Hire following its successful stint as an ASX-listed equipment hire company.
Moore also has plenty of experience with early stage enterprises, and on this note he oversaw Megaport’s transition from a private company to a circa $2 billion diversified telco.
This is the experience he brings to Colinton Capital Partners, and the group’s investment in Alexium International (ASX:AJX) should be seen as a positive endorsement of the business, as well as offering an injection of strategic guidance in terms of negotiating what can sometimes be a challenging path for smaller companies.
Alexium is a performance chemicals provider for advanced materials applications with a focus on flame retardancy and thermal management.
Key markets for Alexium are military uniforms, workwear, and bedding products with its brands including Alexicool® and Alexiflam®.
Colinton’s investment in Alexium appears perfectly timed with the group having battled through the difficult phase of research and development, launching new products and establishing robust relationships with clients/distributors, including the US Defence Force.
In commenting on the progress Alexium has made across these areas, Moore told Hajda, “From our perspective we (Alexium and Colinton collectively) don’t have to establish ourselves from ground zero.
"We have established clients and such a credible market presence that when we say our products work or we can get this, we are already a known and trusted commodity.
"Indeed, one of the factors that really sold us (Colinton) regarding the company’s potential was that it had two proven products, but having established goodwill and credibility you’ve also got a running start in terms of having credibility with customers on each side of the business.
"Especially with big customers like these big suppliers and some of the defence uniform stuff, it can be difficult to build that level of trust.’’
Responding to challenges
Moore’s experience will come to the fore as the group transitions to profitability, accelerates growth, expands its product range, broadens its portfolio of clients and enters new geographic regions.
Accelerated growth and expansion invariably throw up their own challenges with the need to streamline efficiencies and manage costs while also being cognisant of investing for improvement and scale in order to maintain a competitive advantage and optimise margins.
Retaining its competitive position is important as Alexium’s proprietary technology offers a point of difference between it and other industry players, providing decided barriers to entry across its core industries.
It is worth taking a step back to when Colinton first ran the ruler across Alexium and subsequently completed its due diligence to gain an understanding of how it can assist the group in managing the challenges while making the most of upcoming opportunities.
When Moore first decided to have a look at the business he and one of his partners, Jason Phillips, went to the US and met with Alexium’s management as well as a number of suppliers and customers.
Having been impressed with what they saw it was time to invest their money and gain board representation in order to work with management in executing a sound business plan.
On this note Moore said, “One of the things that we identified in diligence was that the company would benefit from was the addition of an expert from the chemicals industry who had considerable experience in the US in very relevant areas within chemicals and had travelled a similar commercialisation life pathway to what lay ahead for Alexium.
“So I revisited my old network as I'd lived in the States for nearly 15 years doing private equity over there.
“And through my friends and from my old working days over there, we identified a small group of potential candidates, and we interviewed them, and the one that stood out to us and we eventually put on the board was Paul Stenson.
“He’s got an excellent background, relevant skill set, the ability to deal and work with management and lengthy experience in working for big chemical companies similar to ICL, enabling him to understand all facets of Alexium’s business.’’
Alexium has made significant progress of recent times and on this note Moore said, “One of the things you're seeing now is a lot of work in progress being made around application of the fire retardant to the mattress sock or a mattress cover if you want to think of it that way.
“That in itself is like, well, we've got great relationships in the mattress industry and we're seen as an innovator in that category, but it's on the cooling agent side it's not on fire retardant, but we're dealing with very similar people.
‘’And our reputation and effectively our goodwill that we've established in the eyes of a customer such as Simmons Serta, and also Simmons SSB is already there.’’
Bear in mind Colinton is a long-term investor (at least four years), and for Alexium to have made as much ground as it has in collaboration with Colinton, the investment group has gone a long way to meeting its charter of being ‘’a constructive investor, leveraging its collective experience and that of its broader networks in order to add value.”
If what Alexium has been able to achieve in a relatively short period of time is a guide to what can be expected in the medium to long-term it is quite likely that the group will be one of Colinton’s ‘brag book’ investments.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.